1490 studies found for:    Melanoma
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental;   Experimental Melanomas
Interventions: Biological: aldesleukin;   Biological: therapeutic autologous lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine phosphate;   Radiation: Total body irradiation
2 Terminated
Has Results
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental
Interventions: Drug: DMF5 Melanoma Reactive TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
3 Completed Phase II Trial of Allovectin-7® for Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma;   Malignant Melanoma;   Skin Cancer
Intervention: Genetic: Allovectin-7®
4 Recruiting FDG-PET in Advanced Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Radiation: [18F]fluorodeoxyglucose;   Other: Molecular assays on biopsied tissue;   Device: positron emission tomography;   Device: computed tomography
5 Not yet recruiting Combi-Neo Study for Stage IV Melanoma
Conditions: Melanoma;   Malignant Melanoma Stage IV;   Metastatic Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Procedure: Surgery
6 Terminated A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Metastatic Melanoma
Intervention: Drug: 131I-TM601
7 Withdrawn Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Conditions: Melanoma;   Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: sorafenib tosylate;   Drug: temsirolimus
8 Recruiting Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIB Melanoma (Locally Advanced);   Stage IIC Melanoma (Locally Advanced);   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma (Limited, Resectable)
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
9 Completed Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Intervention: Drug: allovectin-7
10 Completed Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: allovectin-7;   Drug: allovectin-7/dacarbazine;   Drug: dacarbazine
11 Completed Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: dendritic cell-gp100-MART-1 antigen vaccine;   Drug: sargramostim
12 Recruiting Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab
13 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
14 Recruiting LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma;   BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
15 Completed Comparison of Video-Based Versus Written Patient Education on Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Other: Patient Educational Materials
16 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Conditions: Hereditary Multiple Melanoma;   Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
17 Recruiting Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma
Intervention: Drug: Pazopanib and Paclitaxel
18 Completed Vaccine Therapy in Treating Patients With Advanced Melanoma
Conditions: Intraocular Melanoma;   Malignant Conjunctival Neoplasm;   Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Procedure: biopsy
19 Completed Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: ipilimumab
20 Unknown  FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Intervention: Drug: romidepsin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years